<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002470</url>
  </required_header>
  <id_info>
    <org_study_id>MAOP-5190</org_study_id>
    <secondary_id>CDR0000076667</secondary_id>
    <secondary_id>NBSG-9010</secondary_id>
    <secondary_id>NCI-V90-0197</secondary_id>
    <nct_id>NCT00002470</nct_id>
  </id_info>
  <brief_title>Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors</brief_title>
  <official_title>A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mid-Atlantic Oncology Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Biotherapy Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Interferon alfa may interfere with the growth of the cancer cells.&#xD;
      Combining interferon alfa with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of fluorouracil plus interferon alfa in&#xD;
      treating patients who have advanced metastatic carcinoid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate and duration of remission in patients with&#xD;
           advanced metastatic carcinoid tumors treated with fluorouracil and interferon alfa-2b.&#xD;
&#xD;
        -  Determine the symptomatic response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the survival characteristics of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive fluorouracil IV continuously for 10 weeks and interferon alfa&#xD;
      subcutaneously 3 times a week for 12 weeks. Treatment continues every 12 weeks in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and at weeks 1, 7, and 11 of each course.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1990</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven carcinoid tumor with radiologically confirmed metastatic disease&#xD;
&#xD;
          -  Recurrence after surgery or radiotherapy allowed&#xD;
&#xD;
          -  Must meet at least 1 of the following conditions:&#xD;
&#xD;
               -  Symptomatic carcinoid syndrome not controlled&#xD;
&#xD;
               -  Other systemic symptoms (e.g., weight loss, anorexia)&#xD;
&#xD;
               -  24 hour urinary 5-hydroxyindole acetic acid (5-HIAA) 100 mg or greater&#xD;
&#xD;
               -  Bone metastases&#xD;
&#xD;
               -  Carcinoid heart disease&#xD;
&#xD;
               -  Carcinoid asthma&#xD;
&#xD;
          -  Measurable disease or 24-hour urinary 5-HIAA 50 mg or greater required&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 3.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent infection (no fever for at least 3 days prior to treatment unless fever&#xD;
             due to tumor)&#xD;
&#xD;
          -  No significant medical or psychiatric illness that would preclude study or informed&#xD;
             consent&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell or squamous cell skin&#xD;
             cancer or curatively treated stage I carcinoma of the cervix&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior interferon therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior endocrine therapy allowed&#xD;
&#xD;
          -  Concurrent octreotide allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior surgery allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior fluorinated pyrimidine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Ahlgren, MD</last_name>
    <role>Study Chair</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert K. Oldham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Therapeutics, Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ahlgren JD, Leming PD, Gullo JJ, et al.: Protracted infusional 5-FU (PIF) + alpha2b-interferon (alpha-IFN) in metastatic carcinoid: updated experience with Mid-Atlantic Oncology Program (MAOP) study 5190. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-552, 219, 1995.</citation>
  </results_reference>
  <results_reference>
    <citation>Ahlgren JD, Leming PD, Fryer D, et al.: Protracted infusional 5-FU (PIF) + alpha2b-interferon (alpha-IFN): a well tolerated regimen for palliation of advanced carcinoid: a Mid-Atlantic Oncology Program (MAOP) study. [Abstract] Proceedings of the American Society of Clinical Oncology 12: A-661, 218, 1993.</citation>
  </results_reference>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

